Академический Документы
Профессиональный Документы
Культура Документы
2 0 1 4;3 6(1):15–20
Revista Española de
Cirugía Oral y
Maxilofacial
www.elsevier.es/recom
Original
Historia del artículo: Objetivo: Realizar una revisión de la situación actual en el tratamiento del melanoma de
Recibido el 18 de abril de 2012 mucosa oral (MMO).
Aceptado el 4 de julio de 2012 Describir el protocolo de tratamiento que haya demostrado mejores resultados dada la
On-line el 21 de junio de 2013 experiencia y los estudios realizados por la institución de referencia.
Material y métodos: Los autores realizan una amplia revisión de la literatura abordando las
Palabras clave: nuevas líneas terapéuticas de investigación.
Melanoma Resultados: Descripción del protocolo de tratamiento que siguen en uno de los centros con
Mucosa mayor cáustica en la literatura internacional.
Intraoral Conclusiones: El MMO es una neoplasia maligna poco frecuente, con etiología y patoge-
nia desconocida y un pronóstico infausto. El tratamiento debe basarse en un diagnóstico
temprano y un abordaje multidisciplinar.
© 2012 SECOM. Publicado por Elsevier España, S.L. Todos los derechos reservados.
a b s t r a c t
Keywords: Objective: To review the current situation in the treatment of oral mucosal melanoma. To
Melanoma describe the treatment protocol that has shown better results, given the experience and
Mucosa studies by the reference institution.
Intraoral Methods: The authors conducted an extensive review of the literature addressing the new
lines of therapeutic research.
Results: Description of the treatment regimen followed at one of the most experienced cen-
ters in the international literature.
Conclusions: Oral mucosal melanoma is a rare malignancy with an unknown etiology and
pathogenesis and poor prognosis. Treatment should be centered on early diagnosis and a
multidisciplinary approach.
© 2012 SECOM. Published by Elsevier España, S.L. All rights reserved.
∗
Autor para correspondencia.
Correo electrónico: lorenapingarron@yahoo.es (L. Pingarrón Martín).
1130-0558/$ – see front matter © 2012 SECOM. Publicado por Elsevier España, S.L. Todos los derechos reservados.
http://dx.doi.org/10.1016/j.maxilo.2012.07.001
16 r e v e s p c i r o r a l m a x i l o f a c . 2 0 1 4;3 6(1):15–20
Introducción
I II III IV V VI
a b c d
Classification of vertial and horizontal maxillectomy and midface defect
Vertical classification: I–maxillectomy not causing an oronasal fistula; II–not involving the orbit; III–involving the orbital adnexae with orbital retention; IV–with
orbital enucleation or exenteration; V–orbitomaxillary defect; VI–nasomaxillary defect. Horizontal classification: a–palatal defect only, not involving the dental
alveolus; b–less than or equal to 1/2 unilateral; c–less than or equal to 1/2 bilateral or transverse anterior; d–greater than 1/2 maxillectomy. Letters refer to the
increasing complexity of the dentoalveolar and palatal defect, and qualify the vertical dimension.
Figura 3 – Última clasificación de Brown y Shaw, de las maxilectomías en sus dimensiones horizontal y vertical.
- El primer año: cada 2-4 meses. Los autores declaran no tener ningún conflicto de intereses.
- El segundo año: cada 4-6 meses.
- A partir del tercer año: cada 6 meses. bibliograf í a
5. Wagner M, Morris CG, Werning JW, Mendenhall WM. Mucosal 16. Carlson GW, Page AJ, Cohen C, Parker D, Yaar R, Li A, et al.
melanoma of the head and neck. Am J Clin Oncol. Regional recurrence after negative sentinel lymph node
2008;31:43–8. biopsy for melanoma. Ann Surg. 2008;248:378–86.
6. Chang AE, Karnell LH, Menck HR. The National Cancer Data 17. Saltman BE, Ganly I, Patel SG, Coit DG, Brady MS, Wong RJ.
Base report on cutaneous and noncutaneous melanoma. A Prognostic implication of sentinel lymph node biopsy in
summary of 84,836 cases from the past decade. Cancer. cutaneous head and neck melanoma. Head Neck.
1998;83:1664–78. 2010;32:1686–92.
7. Owens JM, Gomez JA, Byers RM. Malignant melanoma in the 18. Leong SP, Accortt NA, Essner R, Ross M, Gershenwald JE,
palate of a 3-month-old child. Head Neck. 2002;24:91–4. Pockaj B, et al. Impact of sentinel node status and other risk
8. López-Graniel CM, Ochoa-Carrilo FJ, Menese-García A. factors on the clinical outcome of head and neck melanoma
Malignant melanoma of the oral cavity: Diagnosis and patients. Arch Otolaryngol Head Neck Surg. 2006;132:370–3.
treatment experience in a Mexican population. Oral Oncol. 19. Gomez-Rivera F, Santillan A, McMurphey AB, et al. Sentinel
1999;35:425–30. node biopsy in patients with cutaneous melanoma of the
9. Greene GW, Haynes JW, Dozier M, Blumberg JM, Bernier JL. head and neck: recurrence and survival study. Head Neck.
Primary malignant melanoma of the oral mucosa. Oral Surg 2008;30:1284–94.
Oral Med Oral Pathol. 1953;6:1435–43. 20. Owens JM, Roberts DB, Myers JN. The role of postoperative
10. Yang X, Ren GX, Zhang ChP, Zhou GY, Hu YJ, Yang WJ, et al. adjuvant radiation therapy in the treatment of mucosal
Neck dissection and post-operative chemotherapy with melanomas of the head and neck region. Arch Otolaryngol
dimethyl triazeno imidazole carboxamide and cisplatin Head Neck Surg. 2003;129:864–8.
protocol are useful for oral mucosal melanoma. BMC Cancer. 21. Mouawad R, Sebert M, Michels J, Bloch J, Spano JP, Khayat D.
2010;10:623–31. Treatment for metastatic malignant melanoma: old drugs
11. Rinaldo A, Shaha AR, Patel SG, Ferlito A. Primary mucosal and new strategies. Crit Rev Oncol Hematol. 2010;74:27–39.
melanoma of the nasal cavity and paranasal sinuses. Acta 22. Atkins MB. The treatment of metastatic melanoma with
Otolaryngol. 2001;121:979–82. chemotherapy and biologics. Curr Opin Oncol. 1997;9:205–13.
12. Temam S, Mamelle G, Marandas P, Wibault P, Avril MF, Janot F, 23. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ,
et al. Postoperative radiotherapy for primary mucosal Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of
melanoma of the head and neck. Cancer. 2005;103:313–9. high-risk resected cutaneous melanoma: the Eastern
13. Medina JE, Ferlito A, Pellitteri PK, Shaha AR, Khafif A, Cooperative Oncology Group Trial EST 1684. J Clin Oncol.
Devaney KO, et al. Current management of mucosal 1996;14:7–17.
melanoma of the head and neck. J Surg Oncol. 2003;83:116–22. 24. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P,
14. White N, Yap LH, Srivastava S. Lymphadenectomy for Larkin J, et al. Improved survival with vemurafenib in
melanoma in the clinically N1 neck: radical, modified radical, melanoma with BRAF V600E mutation. N Engl J Med.
or selective? J Craniofac Surg. 2009;20:385–8. 2011;364:2507–16.
15. Chao C, Wong SL, Edwards MJ, Ross MI, Reintgen DS, 25. Brown JS, Shaw RJ. Reconstruction of the maxilla and
Noyes RD, et al. Sentinel lymph node biopsy for head and midface: introducing a new classification. Lancet Oncol.
neck melanomas. Ann Surg Oncol. 2003;10:21–6. 2010;11:1001–8.